Join the Oncology Voice Network. Join for Free
Breakthroughs in Oncology Drug Development with Dr. Roy Baynes

Breakthroughs in Oncology Drug Development with Dr. Roy Baynes


Share This Article


Summary

How do world-changing cancer treatments go from concept to reality? Tune in and discover how strategy, leadership, and heart unite to change lives in oncology—listen now.

How do world-changing cancer treatments go from concept to reality? In this episode of the Oncology Voice Network Podcast, host Dr. Kirk Shepard welcomes Dr. Roy Baynes, the Chief Medical Officer of ICON Therapeutics and the architect behind the clinical strategy for Keytruda (pembrolizumab), one of the most transformative cancer therapies of our time. Listen as Dr. Baynes shares his personal journey from academia to industry, his leadership and collaboration philosophy, and the critical decisions that accelerated one drug to impact millions. He reveals how adaptive trials, bold partnerships, clear strategy, and relentless patient focus set new standards—not only for science, but for access and equity in cancer care. From lessons learned at Amgen, Gilead, and Merck, to navigating regulatory relationships and cross-functional teamwork, this episode is a masterclass in what it takes to drive rapid oncology innovation. Dr. Baynes also looks ahead to the future, sharing his optimism for breakthroughs, actionable insights for teams, and why patient-centered purpose should lead every step. Tune in and discover how strategy, leadership, and heart unite to change lives in oncology—listen now.

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN